Why Furiex Pharmaceuticals Inc. Is an Instant Double

Shares of Furiex Pharmaceuticals exploded today, up 145% as the company released data that its drug treating a form of IBS that results in diarrhea passed its phase 3 trials, soundly beating a placebo at the higher dosing.

In this video, Motley Fool health-care analyst David Williamson discusses whether or not he thinks the drug will be approved and what the potential market size could be, and looks at just how high this stock could go.

What's the best way to play the highly volatile biotech space?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

The article Why Furiex Pharmaceuticals Inc. Is an Instant Double originally appeared on Fool.com.

David Williamson owns shares of AbbVie. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.